Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie to present new Elagolix data at ASRM 2016

AbbVie to present new Elagolix data at ASRM 2016

13th October 2016

AbbVie will be sharing a range of endometriosis research insights at the upcoming American Society for Reproductive Medicine (ASRM) scientific congress and expo.

Taking place in Salt Lake City from October 15th to 19th, the event will see AbbVie and development partner Neurocrine Biosciences present data from two replicate phase III studies evaluating the efficacy and safety of their drug Elagolix.

This investigational, orally administered gonadotropin-releasing hormone antagonist is being developed for the treatment of premenopausal women with endometriosis, with the results of these studies showing its benefits in addressing endometriosis-associated pain.

Dr Rob Scott, vice-president for development and chief medical officer at AbbVie, said: "The data highlights the efficacy and safety profile of Elagolix in the treatment of pain associated with endometriosis, and underscores AbbVie's efforts to help address the needs of women suffering from endometriosis."

Additional data detailing the economic burden of endometriosis and endometriosis-related surgery in women across the US will also be presented.

Endometriosis occurs when the cells that normally line the uterus begin to grow outside of the uterus, causing pain and discomfort. It is estimated to affect around one in ten women.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826700-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.